Heart
failure is a morbid disorder characterized by progressive
cardiomyocyte (CM) dysfunction and death. Interest in cell-based therapies
is growing, but sustainability of injected CMs remains a challenge.
To mitigate this, we developed an injectable biomimetic Reverse Thermal
Gel (RTG) specifically engineered to support long-term CM survival.
This RTG biopolymer provided a solution-based delivery vehicle of
CMs, which transitioned to a gel-based matrix shortly after reaching
body temperature. In this study we tested the suitability of this
biopolymer to sustain CM viability. The RTG was biomolecule-functionalized
with poly-l-lysine or laminin. Neonatal rat ventricular myocytes
(NRVM) and adult rat ventricular myocytes (ARVM) were cultured in
plain-RTG and biomolecule-functionalized-RTG both under 3-dimensional
(3D) conditions. Traditional 2D biomolecule-coated dishes were used
as controls. We found that the RTG-lysine stimulated NRVM to spread
and form heart-like functional syncytia. Regarding cell contraction,
in both RTG and RTG-lysine, beating cells were recorded after 21 days.
Additionally, more than 50% (p value < 0.05; n = 5) viable ARVMs, characterized by a well-defined cardiac
phenotype represented by sarcomeric cross-striations, were found in
the RTG-laminin after 8 days. These results exhibit the tremendous
potential of a minimally invasive CM transplantation through our designed
RTG-cell therapy platform.